This medication requires a valid prescription. Please refer to the ‘Prescription Guide’ for details.

Note: We can assist only if the medicine is unavailable in your country.”

Talzenna (talazoparib)

General Description:

Talzenna (talazoparib) is an oral PARP inhibitor used to treat adult patients with HER2-negative locally advanced or metastatic breast cancer who have a germline BRCA mutation (gBRCA).

Getting Talzenna (talazoparib) in India

Talzenna (talazoparib)is approved in the U.S., Europe, and other countries but it is not yet sold in India commercially. Still, patients in India can get this important medicine for their treatment through a special program called the Named Patient Program (NPP).

MitoGENE helps eligible patients get Talzenna (talazoparib) legally and safely, with the support of their treating physician. We take care of all the necessary paperwork, import process, and delivery—while making sure everything follows Indian regulations.

If you or someone you care about requireTalzenna (talazoparib), MitoGENE is here to guide and support you every step of the way.

Disease Indications: HER2-negative metastatic or locally advanced breast cancer with BRCA mutation

Manufacturer:Pfizer Inc.

Usage:Oral

Medicine Approved by:

• Food and Drug Administration (FDA)
• European Medicines Agency (EMA)
• Health Canada
• Therapeutic Goods Administration (TGA)

Available Dosage Form & Package:

• 1 mg capsule – blister pack of 30

Shipping:

Room Temperature Shipping. This medication is shipped using standard delivery methods, ensuring it remains within a controlled room temperature range of 15°C to 25°C throughout transit.

What is Talzenna (talazoparib)?

Talzenna is a prescription medicine used to treat adults with advanced breast cancer who test positive for BRCA gene mutations. It is typically used when the cancer is HER2-negative and has spread beyond the breast.

How does Talzenna work?

Talzenna contains talazoparib, a PARP inhibitor. PARP enzymes help repair damaged DNA in cells. Talzenna blocks PARP, making it harder for cancer cells with BRCA mutations to repair themselves—causing them to die.

Where is Talzenna approved?

• U.S. FDA – Approved October 2018
• EMA – Approved June 2019
• Health Canada – Approved 2019
• TGA (Australia) – Approved 2020

Note: Availability may vary. Consult your doctor for local approval and access status.

What are the possible side effects?

Common side effects include:
• Anemia (low red blood cells)
• Fatigue
• Nausea
• Neutropenia (low white blood cells)
• Headache
• Low platelet count
• Vomiting

Important: Avoid use during pregnancy or breastfeeding.

Note:

Always consult your oncologist to determine if Talzenna is suitable for your condition. Your doctor will assess your BRCA mutation status and overall treatment history.

References:

BreastCancer.org – PARP Inhibitors and BRCA Mutations.

  1. U.S. Food and Drug Administration (FDA). Talzenna Prescribing Information.
  2. European Medicines Agency (EMA). Talzenna Product Details.
  3. National Cancer Institute. Talazoparib Drug Summary.
  4. Pfizer Inc. Product Overview – Talzenna.

How to Access Talzenna (talazoparib) in India in 4 Simple Steps with MitoGENE via the Named Patient Program (NPP)?

If Alunbrig (Brigatinib) is not yet approved or commercially available in India, MitoGENE can assist you in accessing it legally through the Named Patient Program (NPP). Here’s how the process works:

    Upload Prescription

    Upload Patient Consent Form

    Patient Consent Form
    Download

    Please download and complete this form, including your signature, and attach it to the request form or email it to info@mitogene.org along with the patient details.